 Portage Biotech Inc NASDAQ: PRTG acquired the remaining 22 stake in its invariant natural killer T cell iNKT agonist platform and now wholly owns the worldwide rights to its small molecule iNKT agonists, including lead programs PORT-2 and PORT-3. The platform was acquired. 